pharma · Cystic Fibrosis · Hepatitis C
Vertex Pharmaceuticals (Australia)
Vertex Pharmaceuticals (Australia) Pty.
Vertex Pharmaceuticals (Australia) is a pharma organization headquartered in Boston, USA. Primary therapeutic focus areas include Cystic Fibrosis, Hepatitis C, Pain, Chronic Hepatitis C, Acute Pain. NovaPharmaNews links
Company details
- Status
- Public
- HQ
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
- Founded
- 1989
- Employees
- 6,304
- Programs
- 159
- Drugs
- 64
- Patents
- 991
Quick answer
Vertex Pharmaceuticals (Australia) is a pharma organization headquartered in Boston, USA. Primary therapeutic focus areas include Cystic Fibrosis, Hepatitis C, Pain, Chronic Hepatitis C, Acute Pain. NovaPharmaNews links 159 clinical program(s), 11 drug profile(s), and 991 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (61), phase 3 (50), phase 1 (41).
Company snapshot
Vertex Pharmaceuticals (Australia) maintains 159 tracked programs across Cystic Fibrosis, Hepatitis C, Pain, Chronic Hepatitis C, Acute Pain, Hepatitis C, Chronic, Rheumatoid Arthritis, Severe sickle cell disease (SCD), Myotonic Dystrophy, Primary Membranous Nephropathy, Autosomal Dominant Polycystic Kidney Disease (ADPKD), Type 1 Diabetes. Momentum score: 35/100 (30-day delta: n/a). Public regist
- 11 approved product(s) across US/EU regulatory metadata.
- 159 active pipeline program(s) linked via ClinicalTrials.gov.
- 991 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Vertex Pharmaceuticals (Australia). Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
- approval
FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
- approval
FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx
- approval
Vertex launches Journavx after FDA approval for acute pain
Recent coverage
FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
The FDA approved Vertex Pharmaceuticals’ Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults. The decision creates a new non-opioid catalyst to track for BD teams, investors, and analysts.
FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx
The FDA approved Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults, including postoperative pain. The decision gives Vertex the first non-opioid analgesic in this setting and creates a new catalyst set for BD teams, investors, and analysts.
Vertex launches Journavx after FDA approval for acute pain
Vertex’s Journavx (suzetrigine) became the first FDA-approved non-opioid analgesic for moderate to severe acute pain on January 30, 2025. This plan frames the catalyst, label, and upcoming clinical milestones for BD teams, investors, and analysts.
Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
Vertex Pharmaceuticals announced that the FDA has accepted its Biologics License Application for accelerated approval of povetacicept in IgA nephropathy, with a PDUFA target date of November 30, 2026. The filing is supported by positive week 36 interim analysis data.
Top assets
Lead pipeline drugs
- approved
- approved
- approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Vertex Pharmaceuticals (Australia).
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Vertex Pharmaceuticals (Australia).
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Vertex Pharmaceuticals (Australia)?
-
Is Vertex Pharmaceuticals (Australia) publicly traded?
-
What drugs does Vertex Pharmaceuticals (Australia) develop or market?
-
What are the latest developments for Vertex Pharmaceuticals (Australia)?
-
What therapeutic areas does Vertex Pharmaceuticals (Australia) focus on?
Full intelligence profile
Registry synthesis
Grounded overview from trials, patents, coverage, and catalysts.
Vertex Pharmaceuticals (Australia) maintains 159 tracked programs across Cystic Fibrosis, Hepatitis C, Pain, Chronic Hepatitis C, Acute Pain, Hepatitis C, Chronic, Rheumatoid Arthritis, Severe sickle cell disease (SCD), Myotonic Dystrophy, Primary Membranous Nephropathy, Autosomal Dominant Polycystic Kidney Disease (ADPKD), Type 1 Diabetes. Momentum score: 35/100 (30-day delta: n/a).
Public registry data covers pipeline phase, clinical trials, patents, SEC filings, and Nova editorial coverage. HQ: Boston USA. Ticker: VRTX.
Pipeline programs
Placebo — phase phase_3, status completed. Indication: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation. Next milestone: not disclosed (TBD).
IVA — phase phase_3, status completed. Indication: Cystic Fibrosis. Next milestone: not disclosed (TBD).
VX-147 film-coated tablet, VX-147, Coated Placebo Tablet — phase phase_3, status active. Indication: APOL1-mediated Proteinuric Kidney Disease (AMKD). Next milestone: not disclosed (TBD).
Pegylated Interferon Alfa 2a — phase phase_3, status completed. Indication: Hepatitis C. Next milestone: not disclosed (TBD).
Biological/Vaccine — phase phase_3, status active. Indication: Type 1 Diabetes. Next milestone: not disclosed (TBD).
CTX001 — phase phase_3, status active. Indication: Beta-Thalassemia. Next milestone: not disclosed (TBD).
Povetacicept — phase phase_3, status active. Indication: Immunoglobulin A Nephropathy. Next milestone: not disclosed (TBD).
Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion — phase phase_3, status active. Indication: Sickle Cell Disease, Transfusion dependent thalassemia. Next milestone: not disclosed (TBD).
Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR — phase phase_3, status active. Indication: Transfusion-dependent β-thalassemia (TDT). Next milestone: not disclosed (TBD).
Lumacaftor — phase phase_3, status completed. Indication: Cystic Fibrosis. Next milestone: not disclosed (TBD).
VX-880 solution for infusion — phase phase_3, status active. Indication: Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia. Next milestone: not disclosed (TBD).
Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, PLERIXAFOR, BUSULFAN — phase phase_3, status active. Indication: Severe sickle cell disease (SCD). Next milestone: not disclosed (TBD).
Recent Nova coverage
Nova coverage: FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain (2026-06-07).
Nova coverage: FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx (2026-06-07).
Nova coverage: Vertex launches Journavx after FDA approval for acute pain (2026-06-07).
Nova coverage: Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy (2026-06-05).
Registry facts
Registry profile: founded 1989; employees 6304; market cap n/a; revenue n/a; LEI n/a; CIK 0000875320.
Company type: pharma; public/private: public. Data quality score: 0.864.
Catalyst calendar
Catalyst: Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy — type approval, date 2026-06-05.
Catalyst: FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain — type approval, date 2026-06-07.
Catalyst: FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx — type approval, date 2026-06-07.
Catalyst: Vertex launches Journavx after FDA approval for acute pain — type approval, date 2026-06-07.
Competitive peers
Peer: Ultragenyx UK (overlap score 40.0).
Peer: HOFFMANN-LA ROCHE (overlap score 40.0).
Peer: Lakefront Biotherapeutics NV (overlap score 39.8).
Peer: Universal Integrated (overlap score 37.8).
Peer: Chinese University of (overlap score 28.4).
Peer: Indivior Pty (overlap score 27.8).
Peer: Atea Pharmaceuticals (overlap score 27.4).
Peer: Gilead Sciences Ireland (overlap score 25.2).
Competitive positioning reflects therapeutic-area overlap with peer sponsors and recent catalyst activity from trials, regulatory actions, and congress presentations. Data is assembled from ClinicalTrials.gov, SEC EDGAR, openFDA, and NovaPharmaNews articles — not third-party wire republication.
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.